| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 16.05.
| ImmunoGen, Inc. Announces Presentations at 2012 ASCO Annual Meeting on Product Candidates with the Company's TAP Technology | | 37 | Business Wire |
| – Trastuzumab emtansine (T-DM1) EMILIA Phase III data selected
for plenary session; SAR3419 data and additional trastuzumab emtansine
data also being reported
–
ImmunoGen...
Mehr lesen zu:
ImmunoGen, Inc. Announces Presentations at 2012 ASCO Annual Meeting on Product Candidates with the Company's TAP Technology | |
| 10.05.
| IMMUNOGEN INC - 10-Q, Quarterly Report | | 6 | SEC Filings |
| 08.05.
| ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences | | 27 | Business Wire |
| ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops
targeted antibody-based anticancer products, today announced that the
following presentations by...
Mehr lesen zu:
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences | |
| 27.04.
| ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update | | 41 | Business Wire |
| Trastuzumab emtansine (T-DM1) progress includes achievement of
progression-free survival (PFS) endpoint in lead Phase III trial for
HER2+ metastatic breast...
Mehr lesen zu:
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update | |
| 18.04.
| ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2012 Financial Results | | 49 | Business Wire |
| ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
antibody-based anticancer products, today announced that the Company
will host a...
Mehr lesen zu:
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2012 Financial Results | |
| 17.04.
| ImmunoGen (IMGN) Says IND for IMGN853 Now Active | | 4 | StreetInsider.com |
| 17.04.
| ImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853 | | 42 | Business Wire |
| Potential new therapeutic for ovarian cancer, non-small cell lung
cancer (NSCLC) and other solid tumors which over-express folate
receptor 1 (FOLR1).
Achievement...
Mehr lesen zu:
ImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853 | |
| 17.04.
| ImmunoGen (IMGN) Commences IMGN529 Phase I in Patients with NHL | | 4 | StreetInsider.com |
| 17.04.
| ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its Novel IMGN529 Anticancer Compound | | 49 | Business Wire |
| – First of Two Unique ImmunoGen Product Candidates Expected to
Enter Clinic in 2012 –
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
...
Mehr lesen zu:
ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its Novel IMGN529 Anticancer Compound | |
| 30.03.
| Immunogen Rising on Above-Average Volume, Consistent With Trend | | 2 | SmarTrend |
| 30.03.
| Bullish Moving Average Cross by Immunogen | | 2 | SmarTrend |
| 30.03.
| ImmunoGen up 11% on Positive Phase III Results | | 7 | Benzinga.com |
| 30.03.
| From Earlier: ImmunoGen Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial | | 1 | Benzinga.com |
| 30.03.
| ImmunoGen (IMGN) Reports Positive Top-Line Results from T-DM1 EMILIA Phase III | | 1 | StreetInsider.com |
| 30.03.
| ImmunoGen (IMGN) Initiates IMGN901 Phase II | | - | StreetInsider.com |
| 30.03.
| ImmunoGen Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate | | - | Benzinga.com |
| 30.03.
| ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today's Favorable Announcements about Trastuzumab Emtansine (T-DM1) and about IMGN901 | | 33 | Business Wire |
| ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops
targeted anticancer products, today announced that it will host a
conference call at 8:00 am ET on...
Mehr lesen zu:
ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today's Favorable Announcements about Trastuzumab Emtansine (T-DM1) and about IMGN901 | |
| 30.03.
| ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate | | 33 | Business Wire |
| NORTH trial assesses impact of adding IMGN901 to standard care for
first-line treatment of small-cell lung cancer (SCLC).
Trial includes planned...
Mehr lesen zu:
ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate | |
| 30.03.
| ImmunoGen, Genentech Say Breast Cancer Therapy Phase III Trial Results Positive | | 68 | AFX News |
| WASHINGTON (dpa-AFX) - ImmunoGen Inc. (IMGN) Friday reported positive
results from a Phase III trial, dubbed EMILIA, of the anticancer compound
transtuzumab emtansine, which the company...
Mehr lesen zu:
ImmunoGen, Genentech Say Breast Cancer Therapy Phase III Trial Results Positive | |
| 30.03.
| ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial | | 67 | Business Wire |
| Roche has announced lead Phase III trial with trastuzumab emtansine
has met progression-free survival endpoint
Plans to apply for marketing...
Mehr lesen zu:
ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial | |
